If you are taking anticoagulants (blood thinners), your clotting status should be checked frequently. The goal of suppressive therapy is to inhibit growth and/or function of abnormal weight loss and synthroid tissue. Therefore, levothyroxine sodium tablets should not be administered within 4 hours of these agents. 6 Product Characteristics Color ORANGE Score 2 pieces Shape ROUND Size 7mm Flavor Imprint Code Synthroid;25 Contains Packaging # NDC Package Description Multilevel Packaging 1 0074-4341-13 100 TABLET In 1 BOTTLE None 2 0074-4341-19 1000 TABLET In 1 BOTTLE None Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing weight loss and synthroid Date NDA NDA021402 07/24/2002 Synthroid levothyroxine sodium tablets tablet Product Information Product Type HUMAN PRESCRIPTION DRUG NDC Product Code (Source) 0074-4552 Route of Administration ORAL DEA Schedule Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength LEVOTHYROXINE SODIUM (LEVOTHYROXINE) LEVOTHYROXINE SODIUM 50 ug Inactive Ingredients Ingredient Name Strength ACACIA LACTOSE MONOHYDRATE MAGNESIUM STEARATE POVIDONE TALC Product Characteristics Color WHITE Score 2 pieces Shape ROUND Size 7mm Flavor Imprint Code Synthroid;50 Contains Packaging # NDC Package Description Multilevel Packaging 1 0074-4552-13 100 TABLET In 1 BOTTLE None 2 0074-4552-19 1000 TABLET In 1 BOTTLE None 3 0074-4552-11 weight loss and synthroid PACK In 1 BOX, UNIT-DOSE contains a BLISTER PACK 3 10 TABLET In 1 BLISTER PACK This package is contained within the BOX, UNIT-DOSE (0074-4552-11) 4 0074-4552-71 28 TABLET In 1 BOX None Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date NDA NDA021402 07/24/2002 Synthroid levothyroxine sodium tablets tablet Product Information Product Type weight loss and synthroid PRESCRIPTION DRUG NDC Product Code (Source) 0074-5182 Route of Administration ORAL DEA Schedule Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength LEVOTHYROXINE SODIUM (LEVOTHYROXINE) LEVOTHYROXINE SODIUM 75 ug Inactive Ingredients Ingredient Name Strength ACACIA LACTOSE MONOHYDRATE MAGNESIUM STEARATE POVIDONE TALC FD&C RED NO. 27 & 30 Aluminum Lake 200 FD&C Red No. Hypothyroidism during pregnancy is associated with a higher rate of complications, including spontaneous abortion, pre-eclampsia, stillbirth and premature delivery.
synthroid and antidepressants
6 Product Characteristics Color YELLOW Score 2 pieces Shape ROUND Size 7mm Flavor Imprint Code Synthroid;100 Contains Packaging # NDC Package Description Multilevel Packaging 1 0074-6624-13 100 TABLET In 1 BOTTLE None 2 0074-6624-19 1000 TABLET In 1 BOTTLE None 3 0074-6624-11 10 BLISTER PACK In 1 BOX, UNIT-DOSE contains a BLISTER PACK 3 10 TABLET In 1 BLISTER PACK This package is contained within the BOX, UNIT-DOSE (0074-6624-11) Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date NDA NDA021402 07/24/2002 Synthroid levothyroxine sodium tablets tablet Product Information Product Type HUMAN PRESCRIPTION DRUG NDC Product Code (Source) 0074-6594 Route of Administration ORAL DEA Schedule Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength LEVOTHYROXINE SODIUM (LEVOTHYROXINE) LEVOTHYROXINE SODIUM 88 ug Inactive Ingredients Ingredient Name Strength ACACIA LACTOSE MONOHYDRATE MAGNESIUM STEARATE POVIDONE TALC FD&C BLUE NO. Tell your doctor or dentist you are taking Synthroid before you have weight loss and synthroid of any kind. In children, overtreatment can stunt growth. In patients with secondary (pituitary) or tertiary (hypothalamic) hypothyroidism, the levothyroxine sodium dose should be titrated until the patient is clinically euthyroid and the serum free- T4 level is restored to the upper half of the normal range. Do not weight loss and synthroid the mixture for later use. Tell your doctor if you become pregnant during treatment. 6 Aluminum Lake, FD&C Blue No. Patients with Underlying Cardiovascular Disease Exercise caution when administering levothyroxine to patients with cardiovascular disorders and to the elderly in whom there is an increased risk of occult cardiac disease. Take this medicine on an empty stomach, 30 minutes before eating. Notify your weight loss and synthroid immediately if you develop any if the following symptoms. Multum's drug information does not endorse drugs, diagnose patients or recommend therapy. In euthyroid patients, doses within the range of daily hormonal requirements are ineffective for weight reduction. Levothyroxine may also be used for other purposes not listed in this medication guide. Decreases in TBG concentrations are observed in nephrosis, severe hypoproteinemia, severe liver disease, acromegaly, and after androgen or corticosteroid weight loss and synthroid (see also Table 2). Do not start using a new medication without telling your doctor. However, in children with chronic or severe hypothyroidism, an initial dose of 25 mcg/day of levothyroxine sodium is recommended with increments of 25 mcg every 2-4 weeks until the desired effect is achieved. Levothyroxine treats hypothyroidism (low thyroid hormone). Thyroid hormones regulate multiple metabolic processes and play an weight loss and synthroid role in normal growth and development, and normal maturation of the central nervous system and bone. Use Synthroid with caution in the ELDERLY; they may be more sensitive to its effects, especially heart problems.
You may report side effects to the FDA at 1-800-FDA-1088. The information contained in the Thomson Reuters Micromedex products as delivered by Drugs.com weight loss and synthroid intended as an educational aid only. You may report side effects to FDA at 1-800-FDA-1088. Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects . Oral routeTablet Thyroid hormones, including levothyroxine, either alone or with other therapeutic agents, should not be used for the treatment of obesity or weight loss. Specific Patient Populations Hypothyroidism in Adults and in Children in Whom Growth and Puberty are weight loss and synthroid (see WARNINGS and PRECAUTIONS - Laboratory Tests) Therapy may begin at full replacement doses in otherwise healthy weight loss and synthroid less than 50 years old and in those older than 50 years weight loss and synthroid have been recently treated for hyperthyroidism or who have been hypothyroid for only a short time (such as a few months). weight loss and synthroid Sodium Dosing Guidelines for Pediatric Hypothyroidism AGE Daily Dose Per Kg Body Weighta a The weight loss and synthroid should be adjusted based on clinical response and laboratory parameters (see PRECAUTIONS - Laboratory Tests and Pediatric Use). This is a decision you and your doctor will make. Laboratory Tests General The diagnosis of hypothyroidism is confirmed by measuring TSH levels using a sensitive assay (second generation assay sensitivity ≤ 0.1 mIU/L or third generation assay sensitivity ≤ 0.01 mIU/L) and measurement of free-T4. Store at room temperature away from moisture and heat. Version: 6.01. Store Synthroid at room temperature away from moisture and heat. See full prescribing information for dosage and administration.